艾塞那肽对2型糖尿病患者疗效、体重及体质成分的影响(2)
| 第1页 |
参见附件。
[3] Gao Y，Yoon K H，Chuang L M，et al.Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea[J].Diabetes Research and Clinical Practice，2009，83(1)：69-76.
[4] Buse J B，Henry R R，Han J，et al.Effects of exenatide (exendin - 4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes[J].Diabetes Care，2004，27(11)：2628-2635.
[5] De Fronzo R A，Ratner R E，Han J，et al.Effects of exenatide (exendin - 4) on glycemic control and weight over 30 weeks in metformin - treated patients with type 2 diabetes[J].Diabetes Care，2005，28(5)：1092-1100.
[6] Klonoff D C，Buse J B，Nielsen L L，et al.Exenatide effects on diabetes， obesity， cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years[J].Current Medical Research and Opinion，2008，24(1)：275-286.
[7] Sancho V，Trigo M V，Martin-Duce A，et al.Effect of GLP-1 on D-glucose transport， lipolysis and lipogenesis in adipocytes of obese subjects[J].International Journal of Molecular Medicine，2006，17(6)：1133-1137.
[8] Gromada J，Bokvist K，Ding W G，et al.Glucagon-like peptide 1 (7 - 36) amide stimulates exocytosis in human pancreatic beta - cells by both proximal and distal regulatory steps in stimulus-secretion coupling[J].Diabetes，1998，47(1)：57-65.
(收稿日期：2013-12-27) (本文编辑：蔡元元)
您现在查看是摘要介绍页，详见PDF附件。